Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jan-Steffen Kruessel has a total of 197 co-authors. Here are the top co-authors by number of shared publications:

  • Dunja Maria Baston-Buest

    Department of OB/GYN and Reproductive Medicine, UniKiD & UniCareD, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine University Duesseldorf, 40255 Duesseldorf, Germany

    21 shared publications
  • Alexandra Petra Bielfeld

    Department of OB/GYN and Reproductive Medicine, UniKiD & UniCareD, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine University Duesseldorf, 40255 Duesseldorf, Germany

    12 shared publications
  • Alexandra Petra Hess

    University Düsseldorf, Medical Faculty, Department of Obstetrics, Gynecology and REI (UniKiD), Moorenstrasse 5, 40225 Düsseldorf, Germany

    9 shared publications
  • Iwona Scheliga

    Department of OB/GYN and Reproductive Medicine, UniKiD & UniCareD, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine University Duesseldorf, 40255 Duesseldorf, Germany

    7 shared publications
  • Philippos Edimiris

    Department of Obstetrics, Gynecology and REI (UniKiD), Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Germany

    5 shared publications
  • Andrea Schanz

    University Düsseldorf, Medical Faculty, Department of Obstetrics, Gynecology and REI (UniKiD), Moorenstrasse 5, 40225 Düsseldorf, Germany

    4 shared publications

Latest Publications

  • Single or double embryo transfer for infertility: An evaluation of registry data from over 22 000 treatment cycles

    by Jan-Steffen Krüssel, Markus Kimmel, Ute Czeromin, Verona Blumenauer, Sylvia Bartnitzky, Nicole Sänger, Daniel Fehr, Christoph Grewe, Markus Simon Kupka, Sascha Tauchert, et al.

    Over the past decades, assisted reproductive technologies (ART) have seen a worldwide increase in use. However, ART is associated with an increased risk of a multiple pregnancy, which is a major concern. According to data from the German In-vitro...


  • Open Access

    Transport Time Does Not Substantially Alter RNA Expression in Human Ovarian Tissue After Standardized Slow-Freezing for Fertility Preservation

    by Iwona Scheliga, Jana Bender-Liebenthron, Jan-Steffen Kruessel, Alexandra Knebel, Dunja M. Baston-Buest, Alexandra P. Bielfeld

    Background: Fertility preservation aims to maintain reproductive potential in patients undergoing potentially gonadotoxic treatments, increasingly relying on centralized cryobanks requiring ovarian tissue transport. Ovarian tissue cryopreservation is a widely implemented, evidence-based procedure for young women (age 18–35) with a regular ovarian reserve. The ovaries of patients are typically transported overnight to a centralized cryobank for freezing and storage, using a certified hypothermic organ preservation solution such as histidine-tryptophan-ketoglutarate (HTK) at 4–8 °C. The molecular effects of transport on ovarian tissue remain unclear. Methods: In this prospective study of 36 breast cancer patients, we compared whole-transcriptome RNA (RNA-seq) expression in 18 frozen–thawed ovarian biopsies after overnight hypothermic transport followed by slow-freezing versus 18 direct slow-freezing within ≤2 h under FertiPROTEKT-standard conditions. Results: The RNA-seq analysis identified 6 significantly upregulated genes (Bonferroni < 0.05, fold change > 1.5), including histone H2B and mitochondrial NADH dehydrogenase subunit 6 (MT-ND6). The small number of differentially expressed genes suggests only limited transcriptional changes between the two transport conditions. H2B upregulation was confirmed by qPCR, while MT-ND6 showed only moderate levels in RNA-seq but remained stable in qPCR. Immunohistochemical analysis confirmed protein presence and localization in formalin-fixed tissue from four samples, constituting, to our knowledge, the first report of MT-ND6 protein expression in human ovarian tissue. Conclusions: Overall, these results are consistent with subtle changes in chromatin organization and mitochondrial energy metabolism. Since RNA-seq revealed only modest differences in gene expression, with no appreciable up- or downregulation of apoptosis- or damage-related genes after ≤24 h, this indicates tissue stability under the studied combined conditions (transport + cryopreservation). These findings are consistent with the feasibility of the workflow under the studied conditions of centralized ovarian tissue cryobanking combined with overnight transportation and hypothermic HTK solution.


  • Open Access

    In Vitro 3D Model of Human Endometrial Stromal and Trophoblast Cells: Techniques for an Optimized Formation and Cryopreservation of Spheroids

    by Karthika Muthuraj, Iwona Scheliga, Dunja M. Baston-Buest, Jana Bender-Liebenthron, Jan-Steffen Kruessel, Alexandra P. Bielfeld

    Three-dimensional (3D) cell culture models provide physiologically relevant systems that mimic the native endometrial environment better than 2D models and offer reliable platforms to study embryo implantation and maternal–embryo interactions. One widely used 3D culture model is the generation of spheroids. However, standardized and reproducible methods for generating uniform spheroids from trophoblast and endometrial stromal cells are limited. In this study, we established and validated a robust protocol for spheroid formation using human trophoblast (HTR8/SVneo, JEG3) and endometrial stromal (St-T1b, tHESC) cell lines. The protocol was further extended to generate spheroids from decidualized tHESC, representing a novel approach that closely reflects the receptive endometrial environment. Key parameters, including cell concentration and methyl cellulose supplementation, were optimized to produce compact and homogeneous spheroids. Spheroid formation was monitored at defined intervals (0, 8, 24, 32, and 48 h), and decidualized spheroids were assessed up to 72 h. Long-term cryopreservation over 11 months demonstrated high post-thaw viability across all spheroid types, as confirmed by Calcein-AM staining. This standardized workflow provides a reliable 3D model incorporating hormonally primed stromal cells and offers a practical platform to investigate the mechanisms underlying normal and trophoblast invasion in vitro.

  • Open Access

    Live birth rates are unrelated to sex-steroid levels on ET day in a dydrogesterone-based ‘programmed-ovulatory FET’ protocol: a multi-centric prospective cohort study

    by Tanja K Eggersmann, Noemi Hamala, Alexander R Hiller, Marion Depenbusch, Askan Schultze-Mosgau, Philippos Edimiris, Dunja Baston-Büst, Alexandra P Bielfeld, Jan-Steffen Kruessel, Sören von Otte, et al.

    STUDY QUESTION: What are the effects of three-times-a-day 10 mg oral dydrogesterone (DYD), initiated in the late follicular phase of natural menstrual cycles to induce endometrial receptivity for frozen–thawed embryo transfer (FET), on progesterone levels, indicative of ovulation on the day of FET, and how are levels of DYD, 20α-dihydrodydrogesterone (DHD), progesterone (P), and estradiol (E2) on the day of FET associated with clinical outcomes? SUMMARY ANSWER: Late follicular phase initiation of oral 30 mg DYD is compatible with progesterone levels indicative of ovulation in 98% of cases, and DYD, DHD, P, and E2 blood levels on the day of FET do not show a consistent relationship with live birth achievement, whether evaluated in isolation or interaction. WHAT IS KNOWN ALREADY: HRT regimens for FET have come under scrutiny due to: (i) the risk of insufficient progesterone exposure with conventional dosing schemes, and (ii) maternal and fetal risks associated with the iatrogenic absence of a corpus luteum. Oral DYD 10 mg three-times-a-day (tid) is considered unlikely to interfere with ovulation or corpus luteum formation and does not exhibit cross-reactivity with progesterone in ELISA. Therefore, it can be used to induce endometrial receptivity (i.e. to schedule the timing of FET in a natural cycle) and provide luteal phase support (LPS) while allowing ovulation to occur independently of the implantation window and enabling the monitoring of endogenous progesterone serum levels. STUDY DESIGN, SIZE, DURATION: Nested within a multi-centric, prospective, clinical cohort study (NCT03507673), 559 normally cycling women from the routine care population who underwent FET in a spontaneous menstrual cycle (12/2021–8/2023) had DYD, DHD, P, and E2 levels on day of FET measured by high-performance liquid chromatography/tandem mass spectroscopy (HPLC/MS/MS) or commercially available electrochemiluminescence immunoassay (ECLIA). PARTICIPANTS/MATERIALS, SETTING, METHODS: Starting from cycle day 10, women underwent endocrine (E2, LH, and P) and sonographic monitoring until the following criteria were ideally met: a leading follicle ≥16 mm, endometrial thickness ≥6 mm, and E2 ≥ 180 pg/ml. At this point, physicians could initiate oral DYD 10 mg (tid) or, if there was no LH rise in serum, postpone initiation within 2 days of monitoring to align with patient and/or centre preferences (e.g. avoiding weekends). FET for Day 2–Day 5 embryos was performed on Day 3–6 of DYD intake. MAIN RESULTS AND THE ROLE OF CHANCE: DYD and DHD plasma levels on Day 3–6 of intake replicate previous findings. In FET with Day 4 or 5 embryos, serum P levels indicated ovulation in 98.1% (>1.5 ng/ml) and 95.4% (>3.0 ng/ml) of cases and levels were higher (ratio of geometric means 2.88, 95% CI 2.48–3.35) than in FET with Day 2 or 3 embryos. Progesterone levels on day of FET were unrelated (ratio of geometric means 1.13, 95% CI 0.95–1.34) to follicular size (≤16 mm vs >16 mm) and only slightly higher (ratio of geometric means 1.36, 95% CI 1.19–1.56) in cases of serum LH level ≥12.6 IU/l versus 25th percentile) hormone levels (DYD RD −5.3%, 95% CI −14.0 to 3.2, P = 0.227; DHD RD −4.0%, 95% CI −14.6 to 6.0, P = 0.428; Progesterone RD 2.9%, 95% CI −7.0 to 12.3, P = 0.597; E2 RD −3.3%, 95% CI −12.2 to 5.3, P = 0.487). These findings were confirmed across the whole range of hormone values by logistic regression, and no interaction effects of the evaluated hormones on live birth rates were found at the unadjusted significance level 0.05. LIMITATIONS, REASONS FOR CAUTION: All outcomes were assessed only in subjects undergoing FET, not on intention-to-treat. Oral DYD 10 mg (tid), similar to other progestins given to induce endometrial receptivity or for LPS, will likely still interfere with the LH surge, ovulation, and luteal phase characteristics, warranting further investigations using a true natural cycle (NC) as the reference. WIDER IMPLICATIONS OF THE FINDINGS: We propose the term ‘Programmed-Ovulatory (PO-) FET’ for this protocol. The PO-FET protocol enables scheduling the window of implantation, allows ovulation and corpus luteum formation, provides double gestagenic support, and may eliminate the need for control measurements of sex steroids on the day of FET. It allows monitoring of corpus luteum activity during the luteal phase and early pregnancy, is injection-free, and has low drug costs. This protocol needs to be tested in RCTs against other ovulatory FET protocol options, such as the ‘NC FET’ or ‘managed NC FET’. STUDY FUNDING/COMPETING INTEREST(S): The trial was funded through institutional resources of the University Hospital of Schleswig-Holstein, Campus Lübeck. Expenses related to plasma and serum sample handling, storage, shipment, and the HPLC/MS/MS and ELISA analyses of DYD, DHD, estradiol, and progesterone were financially supported by Abbott Products Operations AG (Allschwil, Switzerland). The funding was provided in the form of a research grant to the Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital of Schleswig-Holstein, Campus Lübeck (no grant number applicable). Abbott Products Operations AG had no role in the study design, conduct, data collection, statistical analysis, data interpretation, manuscript preparation, or the decision to submit the article for publication. T.K.E. discloses honoraria from Ferring; travel support from Merck, Ferring, Theramex, and Gedeon-Richter; and receipt of equipment/materials (to institution) from Arthrex and Besins Healthcare, outside the submitted work. N.H. has received travel support from Gedeon-Richter, Ferring, and Merck, outside the submitted work. A.R.H. has received honoraria from Organon and travel support from Merck Serono, Gedeon Richter, and Theramex,...


  • Open Access

    Dead or Alive: Exploratory Analysis of Selected Apoptosis- and Autophagy-Related Proteins in Human Endometrial Stromal Cells of Fertile Females and Their Potential Role During Embryo Implantation

    by Iwona Scheliga, Dunja M. Baston-Buest, Djamila Haramustek, Alexandra Knebel, Jan-Steffen Kruessel, Alexandra P. Bielfeld

    To date, very little is known about how apoptosis and autophagy affect human endometrial stromal cells (ESCs), particularly how these processes might determine the depth of implantation in humans. Before investigating how apoptosis and autophagy might modulate the implantation process in an infertile population, it is necessary to clarify how these processes are regulated in healthy individuals. This study examined the protein expression related to apoptosis and autophagy in primary ESCs from fertile women, particularly in the context of decidualization and embryo contact, using Western blot analysis. This study evaluated the protein expression of apoptosis receptors and autophagy markers during the window of implantation. Previous research has shown that a syndecan 1 (Sdc1) knockdown (kd) in endometrial stromal cell lines increased the sensitivity to apoptosis induced by embryonic stimuli. We aimed to determine if this effect is also present in primary cells and if Sdc1 regulates autophagy. The expression of autophagy- and apoptosis-associated proteins in primary ESCs from fertile individuals was investigated in this preliminary study, along with their impact on the process of human embryo implantation. During decidualization and exposure to embryo contact, we observed an upregulation of apoptosis- and autophagy-related proteins in ESCs. Decidualized ESCs exhibited higher levels of apoptosis receptors, indicating increased sensitivity to embryo-induced apoptosis. Additionally, the increase in basal autophagy proteins suggests a significant role in the implantation process. Sdc1 is potentially involved in regulating apoptosis and autophagy, demonstrating its possible role in modulating implantation-related cell activities. These findings suggest a complex interplay between apoptosis and autophagy in regulating human embryo implantation. The changes in the expression of apoptotic and autophagic proteins in ESCs after decidualization and upon contact with the embryo provide new insights into the cellular mechanisms that underlie successful implantation. These results have potential implications for understanding the pathophysiology of implantation disorders and improving assisted reproductive technologies. The first results of this pilot study need to be verified with a larger sample size in the future.


  • Open Access

    Effect of Waiting Period on Initial Adverse Vaginal Microbiome Composition in IVF-ICSI Patients

    by Alexandra Petra Bielfeld, Dunja Maria Baston-Buest, Philippos Edimiris, Jan-Steffen Kruessel

    Background/Objectives: In this observational prospective cohort study, conducted at the Fertility Centre of the University Hospital, Duesseldorf Germany, the spontaneous reversal capacity and the effect of waiting time on an adverse vaginal microbiome profile in subfertile patients were investigated. Methods: Vaginal swabs of 76 patients were obtained before starting a fertility treatment using a commercially available test to perform a microbiome analysis. Patients with a favorable microbiome profile (“medium” or “high profile”) according to the manufacturer’s algorithm proceeded with the fertility treatment. Patients with an unfavorable microbiome profile (“low profile”) postponed their fertility treatment and were sampled up to four times in each successive cycle or until a shift to a more favorable profile was detected. Results: Initially, 54/76 subjects had a high or medium profile and 23/76 had a low profile. Within 3 months, 75% of patients with an initial low profile shifted to a more favorable profile (7/23 dropouts). The presence of Lactobacillus crispatus in the initial sample was associated with a higher likelihood of a spontaneous shift to a more favorable profile. Conclusions: The vaginal microbiome is subject to strong fluctuations. Even an unfavorable microbiome profile can develop into a favorable microbiome profile within a few months without treatment.


  • Eizellspende – eine Betrachtung aus reproduktionsmedizinischer Perspektive

    by Jan-Steffen Krüssel, Philippos Edimiris, Dunja Maria Baston-Büst, Iwona Scheliga, Jana Bender-Liebenthron, Alexandra Petra Bielfeld

    Die in Deutschland seit 1990 verbotene Eizellspende ist für Frauen mit einer verminderten Anzahl oder Qualität von Eizellen die einzige Option für das Erleben einer Schwangerschaft und die Geburt eines Kindes. Nach fast 40 Jahren haben sich anfängliche Befürchtungen zur Gesundheitsgefährdung der Spenderinnen oder zur psychosozialen Entwicklung der Kinder als wissenschaftlich unbegründet erwiesen. Dennoch wird den Betroffenen in Deutschland die Behandlung unter den hohen medizinischen Qualitätsstandards im eigenen Land weiterhin verwehrt – wissenschaftlich unverständlich.

  • Add-ons in reproductive medicine

    by Nina Bachmann, Jan-Steffen Krüssel

  • Krebs in der Schwangerschaft: Reproduktionsmedizin und Fertilitätserhalt

    by Dunja Maria Baston-Büst, Alexandra Petra Bielfeld, Iwona Scheliga, Philippos Edimiris, Jana Bender-Liebenthron, Jan-Steffen Krüssel

    Krebs in der Schwangerschaft (Gravidität, Grav) tritt derzeit bei etwa einer von 1000 Schwangerschaften auf. Da die Erfüllung eines Kinderwunsches heutzutage häufig erst mit Anfang 30 realisiert wird, liegt die Vermutung nahe, dass die Inzidenz der Grav-assoziierten Krebserkrankungen noch weiter ansteigen wird [1] [2]. Die Diagnose und Behandlung der Grav-assoziierten Krebserkrankung sind eine multidisziplinäre und ethische Herausforderung [3] [4]. Article published online: 28 November 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Nach vorne schauen trotz Krebs? – Möglichkeiten des Fertilitätserhalts in der Schwangerschaft

    by Dunja Baston-Büst, Alexandra P. Bielfeld, Iwona Scheliga, Philippos Edimiris, Jana Bender-Liebenthron, Jan-Steffen Krüssel